Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 50 entries
Sorted by: Best Match Show Resources per page
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.

Therapeutic advances in medical oncology

Magios N, Bozorgmehr F, Volckmar AL, Kazdal D, Kirchner M, Herth FJ, Heussel CP, Eichhorn F, Meister M, Muley T, Elshafie RA, Fischer JR, Faehling M, Kriegsmann M, Schirmacher P, Bischoff H, Stenzinger A, Thomas M, Christopoulos P.
PMID: 34408792
Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509. doi: 10.1177/1758835921996509. eCollection 2021.

BACKGROUND: Epidermal growth factor receptor-mutated (EGFRMETHODS: EGFRRESULTS: A total of 207 patients received erlotinib (37%), gefitinib (16%) or afatinib (47%). The median age was 66 years, with a predominance of female (70%), never/light-smokers (69%). T790M testing was performed in...

Cite
Magios N, Bozorgmehr F, Volckmar AL, et al. Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther Adv Med Oncol. 2021;13:1758835921996509doi: 10.1177/1758835921996509.
Magios, N., Bozorgmehr, F., Volckmar, A. L., Kazdal, D., Kirchner, M., Herth, F. J., Heussel, C. P., Eichhorn, F., Meister, M., Muley, T., Elshafie, R. A., Fischer, J. R., Faehling, M., Kriegsmann, M., Schirmacher, P., Bischoff, H., Stenzinger, A., Thomas, M., & Christopoulos, P. (2021). Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic advances in medical oncology, 131758835921996509. https://doi.org/10.1177/1758835921996509
Magios, Nikolaus, et al. "Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer." Therapeutic advances in medical oncology vol. 13 (2021): 1758835921996509. doi: https://doi.org/10.1177/1758835921996509
Magios N, Bozorgmehr F, Volckmar AL, Kazdal D, Kirchner M, Herth FJ, Heussel CP, Eichhorn F, Meister M, Muley T, Elshafie RA, Fischer JR, Faehling M, Kriegsmann M, Schirmacher P, Bischoff H, Stenzinger A, Thomas M, Christopoulos P. Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509. doi: 10.1177/1758835921996509. eCollection 2021. PMID: 34408792; PMCID: PMC8366107.
Copy Download .nbib Format: NLM
Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition.

Cancers

Baum P, Taber S, Erdmann S, Muley T, Kriegsmann M, Christopoulos P, Thomas M, Winter H, Pfannschmidt J, Eichhorn ME.
PMID: 33920161
Cancers (Basel). 2021 Apr 10;13(8). doi: 10.3390/cancers13081812.

The current pT3N0 category represents a heterogeneous subgroup involving tumor size, separate tumor nodes in one lobe, and locoregional growth pattern. We aim to validate outcomes according to the eighth edition of the TNM staging classification. A total of...

Cite
Baum P, Taber S, Erdmann S, et al. Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. Cancers (Basel). 2021;13(8)doi: 10.3390/cancers13081812.
Baum, P., Taber, S., Erdmann, S., Muley, T., Kriegsmann, M., Christopoulos, P., Thomas, M., Winter, H., Pfannschmidt, J., & Eichhorn, M. E. (2021). Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. Cancers, 13(8), . https://doi.org/10.3390/cancers13081812
Baum, Philip, et al. "Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition." Cancers vol. 13,8 (2021). doi: https://doi.org/10.3390/cancers13081812
Baum P, Taber S, Erdmann S, Muley T, Kriegsmann M, Christopoulos P, Thomas M, Winter H, Pfannschmidt J, Eichhorn ME. Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. Cancers (Basel). 2021 Apr 10;13(8). doi: 10.3390/cancers13081812. PMID: 33920161; PMCID: PMC8068959.
Copy Download .nbib Format: NLM
Chemical Synthesis and Semisynthesis of Lipidated Proteins.

Angewandte Chemie (International ed. in English)

Hanna C, Kriegesmann J, Dowman L, Becker C, Payne RJ.
PMID: 34611966
Angew Chem Int Ed Engl. 2021 Oct 06; doi: 10.1002/anie.202111266. Epub 2021 Oct 06.

Lipidation is a ubiquitous modification of peptides and proteins that can occur either co- or post-translationally. An array of different lipid classes can adorn proteins and has been shown to influence a number of crucial biological activities, including the...

Cite
Hanna C, Kriegesmann J, Dowman L, et al. Chemical Synthesis and Semisynthesis of Lipidated Proteins. Angew Chem Int Ed Engl. 2021;doi: 10.1002/anie.202111266.
Hanna, C., Kriegesmann, J., Dowman, L., Becker, C., & Payne, R. J. (2021). Chemical Synthesis and Semisynthesis of Lipidated Proteins. Angewandte Chemie (International ed. in English), . https://doi.org/10.1002/anie.202111266
Hanna, Cameron, et al. "Chemical Synthesis and Semisynthesis of Lipidated Proteins." Angewandte Chemie (International ed. in English) vol. (2021). doi: https://doi.org/10.1002/anie.202111266
Hanna C, Kriegesmann J, Dowman L, Becker C, Payne RJ. Chemical Synthesis and Semisynthesis of Lipidated Proteins. Angew Chem Int Ed Engl. 2021 Oct 06; doi: 10.1002/anie.202111266. Epub 2021 Oct 06. PMID: 34611966.
Copy Download .nbib Format: NLM
Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy.

Journal of Cancer

Kriegsmann M, Casadonte R, Maurer N, Stoehr C, Erlmeier F, Moch H, Junker K, Zgorzelski C, Weichert W, Schwamborn K, Deininger SO, Gaida M, Mechtersheimer G, Stenzinger A, Schirmacher P, Hartmann A, Kriegsmann J, Kriegsmann K.
PMID: 32922548
J Cancer. 2020 Aug 21;11(20):6081-6089. doi: 10.7150/jca.47698. eCollection 2020.

No abstract available.

Cite
Kriegsmann M, Casadonte R, Maurer N, et al. Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. J Cancer. 2020;11(20):6081-6089doi: 10.7150/jca.47698.
Kriegsmann, M., Casadonte, R., Maurer, N., Stoehr, C., Erlmeier, F., Moch, H., Junker, K., Zgorzelski, C., Weichert, W., Schwamborn, K., Deininger, S. O., Gaida, M., Mechtersheimer, G., Stenzinger, A., Schirmacher, P., Hartmann, A., Kriegsmann, J., & Kriegsmann, K. (2020). Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. Journal of Cancer, 11(20), 6081-6089. https://doi.org/10.7150/jca.47698
Kriegsmann, Mark, et al. "Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy." Journal of Cancer vol. 11,20 (2020): 6081-6089. doi: https://doi.org/10.7150/jca.47698
Kriegsmann M, Casadonte R, Maurer N, Stoehr C, Erlmeier F, Moch H, Junker K, Zgorzelski C, Weichert W, Schwamborn K, Deininger SO, Gaida M, Mechtersheimer G, Stenzinger A, Schirmacher P, Hartmann A, Kriegsmann J, Kriegsmann K. Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. J Cancer. 2020 Aug 21;11(20):6081-6089. doi: 10.7150/jca.47698. eCollection 2020. PMID: 32922548; PMCID: PMC7477404.
Copy Download .nbib Format: NLM
Evolution of 14-Connected Zr.

ACS applied materials & interfaces

Hurlock MJ, Hao L, Kriegsman KW, Guo X, O'Keeffe M, Zhang Q.
PMID: 34124879
ACS Appl Mater Interfaces. 2021 Jun 14; doi: 10.1021/acsami.1c07701. Epub 2021 Jun 14.

Two new zirconium MOFs, WSU-6 and WSU-7, were synthesized through postsynthetic modifications. In both cases, linker insertion was conducted on a MOF consisting of eight-connected (8-c) Zr

Cite
Hurlock MJ, Hao L, Kriegsman KW, et al. Evolution of 14-Connected Zr. ACS Appl Mater Interfaces. 2021;doi: 10.1021/acsami.1c07701.
Hurlock, M. J., Hao, L., Kriegsman, K. W., Guo, X., O'Keeffe, M., & Zhang, Q. (2021). Evolution of 14-Connected Zr. ACS applied materials & interfaces, . https://doi.org/10.1021/acsami.1c07701
Hurlock, Matthew J, et al. "Evolution of 14-Connected Zr." ACS applied materials & interfaces vol. (2021). doi: https://doi.org/10.1021/acsami.1c07701
Hurlock MJ, Hao L, Kriegsman KW, Guo X, O'Keeffe M, Zhang Q. Evolution of 14-Connected Zr. ACS Appl Mater Interfaces. 2021 Jun 14; doi: 10.1021/acsami.1c07701. Epub 2021 Jun 14. PMID: 34124879.
Copy Download .nbib Format: NLM
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.

Cancer immunology, immunotherapy : CII

Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A.
PMID: 34125345
Cancer Immunol Immunother. 2021 Jun 14; doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14.

INTRODUCTION: The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incompletely understood.METHODS: We performed comparative...

Cite
Budczies J, Kirchner M, Kluck K, et al. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2021;doi: 10.1007/s00262-021-02981-w.
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J., Winter, H., Meister, M., Muley, T., Goldmann, T., Fröhling, S., Wermke, M., Waller, C. F., Tufman, A., Reck, M., Peters, S., Schirmacher, P., Thomas, M., Christopoulos, P., & Stenzinger, A. (2021). Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer immunology, immunotherapy : CII, . https://doi.org/10.1007/s00262-021-02981-w
Budczies, Jan, et al. "Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma." Cancer immunology, immunotherapy : CII vol. (2021). doi: https://doi.org/10.1007/s00262-021-02981-w
Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jun 14; doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14. PMID: 34125345.
Copy Download .nbib Format: NLM
TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease.

Science immunology

O'Neill TJ, Seeholzer T, Gewies A, Gehring T, Giesert F, Hamp I, Graß C, Schmidt H, Kriegsmann K, Tofaute MJ, Demski K, Poth T, Rosenbaum M, Schnalzger T, Ruland J, Göttlicher M, Kriegsmann M, Naumann R, Heissmeyer V, Plettenburg O, Wurst W, Krappmann D.
PMID: 34767456
Sci Immunol. 2021 Nov 12;6(65):eabh2095. doi: 10.1126/sciimmunol.abh2095. Epub 2021 Nov 12.

[Figure: see text].

Cite
O'Neill TJ, Seeholzer T, Gewies A, et al. TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease. Sci Immunol. 2021;6(65):eabh2095doi: 10.1126/sciimmunol.abh2095.
O'Neill, T. J., Seeholzer, T., Gewies, A., Gehring, T., Giesert, F., Hamp, I., Graß, C., Schmidt, H., Kriegsmann, K., Tofaute, M. J., Demski, K., Poth, T., Rosenbaum, M., Schnalzger, T., Ruland, J., Göttlicher, M., Kriegsmann, M., Naumann, R., Heissmeyer, V., Plettenburg, O., Wurst, W., & Krappmann, D. (2021). TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease. Science immunology, 6(65), eabh2095. https://doi.org/10.1126/sciimmunol.abh2095
O'Neill, Thomas J, et al. "TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease." Science immunology vol. 6,65 (2021): eabh2095. doi: https://doi.org/10.1126/sciimmunol.abh2095
O'Neill TJ, Seeholzer T, Gewies A, Gehring T, Giesert F, Hamp I, Graß C, Schmidt H, Kriegsmann K, Tofaute MJ, Demski K, Poth T, Rosenbaum M, Schnalzger T, Ruland J, Göttlicher M, Kriegsmann M, Naumann R, Heissmeyer V, Plettenburg O, Wurst W, Krappmann D. TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease. Sci Immunol. 2021 Nov 12;6(65):eabh2095. doi: 10.1126/sciimmunol.abh2095. Epub 2021 Nov 12. PMID: 34767456.
Copy Download .nbib Format: NLM
Ki-67 expression in pulmonary tumors-reply.

Translational lung cancer research

Kriegsmann M, Warth A.
PMID: 27827467
Transl Lung Cancer Res. 2016 Oct;5(5):552-553. doi: 10.21037/tlcr.2016.10.12.

No abstract available.

Cite
Kriegsmann M, Warth A. Ki-67 expression in pulmonary tumors-reply. Transl Lung Cancer Res. 2016;5(5):552-553doi: 10.21037/tlcr.2016.10.12.
Kriegsmann, M., & Warth, A. (2016). Ki-67 expression in pulmonary tumors-reply. Translational lung cancer research, 5(5), 552-553. https://doi.org/10.21037/tlcr.2016.10.12
Kriegsmann, Mark, and Warth, Arne. "Ki-67 expression in pulmonary tumors-reply." Translational lung cancer research vol. 5,5 (2016): 552-553. doi: https://doi.org/10.21037/tlcr.2016.10.12
Kriegsmann M, Warth A. Ki-67 expression in pulmonary tumors-reply. Transl Lung Cancer Res. 2016 Oct;5(5):552-553. doi: 10.21037/tlcr.2016.10.12. PMID: 27827467; PMCID: PMC5099518.
Copy Download .nbib Format: NLM
Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma.

Cancers

Casadonte R, Kriegsmann M, Kriegsmann K, Hauk I, Meliß RR, Müller CSL, Kriegsmann J.
PMID: 34206844
Cancers (Basel). 2021 Jun 26;13(13). doi: 10.3390/cancers13133197.

The discrimination of malignant melanoma from benign nevi may be difficult in some cases. For this reason, immunohistological and molecular techniques are included in the differential diagnostic toolbox for these lesions. These methods are time consuming when applied subsequently...

Cite
Casadonte R, Kriegsmann M, Kriegsmann K, et al. Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma. Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133197.
Casadonte, R., Kriegsmann, M., Kriegsmann, K., Hauk, I., Meliß, R. R., Müller, C. S. L., & Kriegsmann, J. (2021). Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma. Cancers, 13(13), . https://doi.org/10.3390/cancers13133197
Casadonte, Rita, et al. "Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133197
Casadonte R, Kriegsmann M, Kriegsmann K, Hauk I, Meliß RR, Müller CSL, Kriegsmann J. Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma. Cancers (Basel). 2021 Jun 26;13(13). doi: 10.3390/cancers13133197. PMID: 34206844; PMCID: PMC8267712.
Copy Download .nbib Format: NLM
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer.

Frontiers in oncology

Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar AL, Lusky F, Diekmann L, Liersch S, Faehling M, Muley T, Kriegsmann M, Benesova K, Stenzinger A, Thomas M, Christopoulos P.
PMID: 34268127
Front Oncol. 2021 Jun 29;11:703893. doi: 10.3389/fonc.2021.703893. eCollection 2021.

INTRODUCTION: PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management.METHODS: We analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012 to 2020 in a German academic center.RESULTS: IrAE...

Cite
Daniello L, Elshiaty M, Bozorgmehr F, et al. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Front Oncol. 2021;11:703893doi: 10.3389/fonc.2021.703893.
Daniello, L., Elshiaty, M., Bozorgmehr, F., Kuon, J., Kazdal, D., Schindler, H., Shah, R., Volckmar, A. L., Lusky, F., Diekmann, L., Liersch, S., Faehling, M., Muley, T., Kriegsmann, M., Benesova, K., Stenzinger, A., Thomas, M., & Christopoulos, P. (2021). Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in oncology, 11703893. https://doi.org/10.3389/fonc.2021.703893
Daniello, Lea, et al. "Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer." Frontiers in oncology vol. 11 (2021): 703893. doi: https://doi.org/10.3389/fonc.2021.703893
Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar AL, Lusky F, Diekmann L, Liersch S, Faehling M, Muley T, Kriegsmann M, Benesova K, Stenzinger A, Thomas M, Christopoulos P. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Front Oncol. 2021 Jun 29;11:703893. doi: 10.3389/fonc.2021.703893. eCollection 2021. PMID: 34268127; PMCID: PMC8277237.
Copy Download .nbib Format: NLM
Correction to "Evolution of 14-connected Zr.

ACS applied materials & interfaces

Hurlock MJ, Hao L, Kriegsman KW, Guo X, O'Keeffe M, Zhang Q.
PMID: 34382762
ACS Appl Mater Interfaces. 2021 Aug 25;13(33):40155. doi: 10.1021/acsami.1c11786. Epub 2021 Aug 12.

No abstract available.

Cite
Hurlock MJ, Hao L, Kriegsman KW, et al. Correction to "Evolution of 14-connected Zr. ACS Appl Mater Interfaces. 2021;13(33):40155doi: 10.1021/acsami.1c11786.
Hurlock, M. J., Hao, L., Kriegsman, K. W., Guo, X., O'Keeffe, M., & Zhang, Q. (2021). Correction to "Evolution of 14-connected Zr. ACS applied materials & interfaces, 13(33), 40155. https://doi.org/10.1021/acsami.1c11786
Hurlock, Matthew J, et al. "Correction to "Evolution of 14-connected Zr." ACS applied materials & interfaces vol. 13,33 (2021): 40155. doi: https://doi.org/10.1021/acsami.1c11786
Hurlock MJ, Hao L, Kriegsman KW, Guo X, O'Keeffe M, Zhang Q. Correction to "Evolution of 14-connected Zr. ACS Appl Mater Interfaces. 2021 Aug 25;13(33):40155. doi: 10.1021/acsami.1c11786. Epub 2021 Aug 12. PMID: 34382762.
Copy Download .nbib Format: NLM
Cytoreductive Thoracic Surgery Combined with Hyperthermic Chemoperfusion for Pleural Malignancies: A Single-Center Experience.

Respiration; international review of thoracic diseases

Klotz LV, Gruenewald C, Bulut EL, Eichhorn F, Thomas M, Shah R, Kriegsmann M, Schmidt W, Kofler O, Winter H, Eichhorn ME.
PMID: 34384085
Respiration. 2021;100(12):1165-1173. doi: 10.1159/000517334. Epub 2021 Aug 12.

BACKGROUND: Lung-sparing cytoreductive surgery by extended pleurectomy and decortication (EPD) in combination with hyperthermic intrathoracic chemoperfusion (HITOC) forms a promising treatment strategy for malignant pleural mesothelioma and recurrent pleural thymic malignancies.OBJECTIVES: The objective of this study was to scrutinize...

Cite
Klotz LV, Gruenewald C, Bulut EL, et al. Cytoreductive Thoracic Surgery Combined with Hyperthermic Chemoperfusion for Pleural Malignancies: A Single-Center Experience. Respiration. 2021;100(12):1165-1173doi: 10.1159/000517334.
Klotz, L. V., Gruenewald, C., Bulut, E. L., Eichhorn, F., Thomas, M., Shah, R., Kriegsmann, M., Schmidt, W., Kofler, O., Winter, H., & Eichhorn, M. E. (2021). Cytoreductive Thoracic Surgery Combined with Hyperthermic Chemoperfusion for Pleural Malignancies: A Single-Center Experience. Respiration; international review of thoracic diseases, 100(12), 1165-1173. https://doi.org/10.1159/000517334
Klotz, Laura V, et al. "Cytoreductive Thoracic Surgery Combined with Hyperthermic Chemoperfusion for Pleural Malignancies: A Single-Center Experience." Respiration; international review of thoracic diseases vol. 100,12 (2021): 1165-1173. doi: https://doi.org/10.1159/000517334
Klotz LV, Gruenewald C, Bulut EL, Eichhorn F, Thomas M, Shah R, Kriegsmann M, Schmidt W, Kofler O, Winter H, Eichhorn ME. Cytoreductive Thoracic Surgery Combined with Hyperthermic Chemoperfusion for Pleural Malignancies: A Single-Center Experience. Respiration. 2021;100(12):1165-1173. doi: 10.1159/000517334. Epub 2021 Aug 12. PMID: 34384085.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 50 entries